-
公开(公告)号：US10729809B2
公开(公告)日：2020-08-04
申请号：US14849509
申请日：2015-09-09
Applicant: Osiris Therapeutics, Inc.
Inventor： Thomas E. Uveges , Jin-Qiang Kuang , Alla Danilkovitch , S. Michael Sinclair , Sandra D. Geraghty
Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.
-
公开(公告)号：USD843587S1
公开(公告)日：2019-03-19
申请号：US29587468
申请日：2016-12-13
Applicant: OSIRIS THERAPEUTICS, INC.
Designer： Yi Duan-Arnold , Alexandra Gyurdieva
-
公开(公告)号：US20170136071A1
公开(公告)日：2017-05-18
申请号：US15274100
申请日：2016-09-23
Applicant: Osiris Therapeutics, Inc.
Inventor： Alla Danilkovitch , Yi Duan-Arnold , Matthew Moorman , Anne Lerch , Jin-Qiang Kuang
Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.
-
公开(公告)号：USD776823S1
公开(公告)日：2017-01-17
申请号：US29520402
申请日：2015-03-13
Applicant: OSIRIS THERAPEUTICS, INC.
Designer： Yi Duan-Arnold , Alexandra Gyurdieva
-
公开(公告)号：US20160310280A1
公开(公告)日：2016-10-27
申请号：US15079867
申请日：2016-03-24
Applicant: Osiris Therapeutics, Inc.
Inventor： Alla Danilkovitch , Jinqiang Kuang , Steven Michael Sinclair
CPC classification number: A61F2/30756 , A61F2/3094 , A61F2/3872 , A61F2002/30006 , A61F2002/30047 , A61F2002/30807 , A61F2250/00 , A61F2310/00371 , A61L27/3604 , A61L27/3612 , A61L27/3654 , A61L27/3852 , A61L27/54 , A61L2300/414
Abstract: Disclosed are compositions comprising a meniscal tissue. For example, disclosed are compositions comprising a meniscal tissue, wherein the meniscal tissue comprises one or more engineered channels. Disclosed are compositions comprising a meniscal tissue comprising viable cells native to the meniscal tissue and devitalized blood vessels. Disclosed are compositions comprising a previously cryopreserved meniscal tissue, wherein after cryopreservation and subsequent thawing the meniscal tissue comprises a) cells native to the meniscal tissue and greater than 30% of the cells are viable, b) extracellular matrix that is native to the meniscal tissue, c) one or more growth factors that are native to the meniscal tissue, and d) depleted amounts of one or more types of functional immunogenic cells. Also disclosed are methods of producing and using these compositions comprising meniscal tissue.
Abstract translation: 公开了包含半月板组织的组合物。 例如，所公开的是包含半月板组织的组合物，其中所述半月板组织包括一个或多个工程化通道。 公开的是包含半月板组织的组合物，其包含半月板组织天然的活细胞和失活的血管。 公开了包含先前低温保存的半月板组织的组合物，其中在冷冻保存和随后解冻之后，半月板组织包含a）半月板组织天然的细胞，并且大于30％的细胞是活的，b）对半月板组织是天然的细胞外基质 c）一种或多种对半月板组织天然的生长因子，和d）一种或多种类型的功能性免疫原性细胞的耗尽量。 还公开了生产和使用包含半月板组织的这些组合物的方法。
-
Patent Agency Ranking
公开(公告)号：US20150140057A1
公开(公告)日：2015-05-21
申请号：US14464123
申请日：2014-08-20
Applicant: Osiris Therapeutics, Inc.
Inventor： Dana Sue Yoo , Jin-Qiang Kuang , Jaime Paden , Scott A. Maxson , Alla Danilkovitch , Erasmo Lopez , Samson Tom
CPC classification number: A61L27/3612 , A61K35/32 , A61K38/014 , A61L27/24 , A61L27/3608 , A61L27/3654 , A61L27/3683 , A61L27/3687 , A61L27/3691 , A61L27/3817 , A61L27/3852 , A61L27/50 , A61L27/54 , A61L27/56 , A61L2300/414 , A61L2300/64 , A61L2430/06
Abstract: This invention provides porated cartilage products, methods of producing porated cartilage products, and methods of treating subjects by administering cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.
Abstract translation: 本发明提供了开放的软骨产品，生产门软骨产品的方法，以及通过施用软骨制品治疗受试者的方法。 任选地，软骨产品的尺寸，开口和消化以提供柔性软骨产品。 任选地，软骨产品包括活的软骨细胞，生物活性因子如软骨形成因子和II型胶原蛋白。 任选地，软骨产品是非免疫原性的。
-
公开(公告)号：US20150010609A1
公开(公告)日：2015-01-08
申请号：US14272343
申请日：2014-05-07
Applicant: Osiris Therapeutics, Inc.
Inventor： Samson Tom , Alla Danilkovitch , Dana Yoo , Timothy Jansen , Jin-Qiang Kuang , Jennifer Michelle Marconi
CPC classification number: A61K35/50 , A01N1/0221 , A61K38/1825 , A61K38/1841 , A61K38/57 , A61L27/3604 , A61L27/54 , A61L2300/412 , A61L2300/64 , C12N5/0605 , C12N2501/115
Abstract: Provided herein is a placental membrane product comprising an immunocompatible chorionic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing or tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to exclude bacteria, to inhibit bacterial activity, or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.
Abstract translation: 本文提供了包含免疫兼容性绒毛膜的胎盘膜产品。 这样的胎盘膜产品可以在冷冻保存后含有治疗因子和解冻后的活细胞。 胎盘膜产品可用于伤口愈合或组织修复/再生，因为它们能够促进血管生成，减少炎症，减少瘢痕形成以及促进愈合的其它方法。 本技术涉及保护受伤或损坏的组织的产品，或作为排除细菌的覆盖物，抑制细菌活性或促进组织愈合或生长的产品。 该领域还涉及这种膜衍生产品的制造方法和使用方法。
-
18.发明申请Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions 有权包含活力胎盘分散体的治疗产品的制造方法公开(公告)号：US20140127177A1
公开(公告)日：2014-05-08
申请号：US14070040
申请日：2013-11-01
Applicant: Osiris Therapeutics, Inc.
Inventor： Samson Tom , Alla Danilkovitch , Dana Yoo , Timothy Jansen , Jin Qiang Kuang , Jennifer Michelle Marconi
IPC: A61K35/50
CPC classification number: A61K35/28 , A01N1/0221 , A61K35/50 , A61K38/1825 , A61K38/1841 , A61K38/39 , A61K38/57 , C12N5/0605 , C12N2500/02 , C12N2501/115 , C12N2502/025
Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.
Abstract translation: 本发明提供了包含胎盘细胞的流体治疗性胎盘产物和包含胎盘因子的胎盘分散体。 胎盘细胞和胎盘分散体来源于胎盘组织。 胎盘组织可以任选地是羊膜，绒毛膜或消化滋养层的绒毛膜。 本发明的胎盘产品可用于通过将胎盘产品应用于损伤来治疗患有组织损伤（例如伤口或烧伤）的患者。 类似的应用可用于韧带和腱修复以及植入手术如骨移植。
-
19.发明申请公开(公告)号：US20140030235A1
公开(公告)日：2014-01-30
申请号：US13951685
申请日：2013-07-26
Applicant: Osiris Therapeutics, Inc.
Inventor： Timothy Varney , Charles Randal Mills , Alla Danilkovitch
IPC: A61K35/28
CPC classification number: A61K35/28 , A61K2035/124 , C12N5/0663 , C12N15/85
Abstract: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.
Abstract translation: 一种在动物中治疗遗传疾病或病症例如囊性纤维化，威尔逊氏症，肌萎缩性侧索硬化或多囊肾病的方法，包括以有效治疗遗传疾病的量向所述动物间充质干细胞施用 或动物的紊乱。
-
公开(公告)号：US20130259841A1
公开(公告)日：2013-10-03
申请号：US13906592
申请日：2013-05-31
Applicant: Osiris Therapeutics, Inc.
Inventor： Alla Danilkovitch , Diane Carter , Alicia Tyrell , Simon Bubnic , Michelle Marcelino , Rodney Monroy
IPC: A61K35/28
CPC classification number: C12N5/0662 , A61K35/28 , A61K2035/122 , C12N5/0663 , C12N2501/25 , G01N2333/525
Abstract: Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
Abstract translation: 表达至少13pg / 106细胞量的TNF-α受体I型的间充质干细胞。 这种间充质干细胞抑制淋巴细胞的增殖，特别可用于治疗移植物抗宿主病。
-
-
-
-
-
-
-
-
-
Search Results
571
records
(took 0.03 seconds)
